Elderly patients with pancreatic cancer.

Abstract

Pancreatic cancer marked significant increase of incidence during the last decades in the elderly population. Despite the certain increase of incidence there are no international guidelines for elderly patients who are suffering from pancreatic cancer. During the ASCO Annual Meeting 2014, two abstracts focusing on elderly patients suffering from different histological types of pancreatic cancer were presented. The first retrospective study (Abstract #4119) showed the benefit of the systemic treatment on overall survival for elderly patients with stage IV pancreatic adenocarcinoma. The second retrospective study (Abstract #4112) demonstrates the positive effect of somatostatin analogue (octreotide-LAR) treatment on overall survival for elderly patients with neuroendocrine pancreatic carcinoma.

• Authors: Andromachi S Kougioumtzopoulou, Kostas N Syrigos, Muhammad Wasif Saif
• Journal: JOP : Journal of the pancreas (JOP) Vol. 15 Issue 4 Pg. 322-5 (Jul 28 2014) ISSN: 1590-8577 [Electronic] Italy
• PMID: 25076333 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Somatostatin
• Octreotide

Topics

• Adenocarcinoma (drug therapy, pathology)
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Female
• Humans
• Male
• Neoplasm Metastasis
• Neuroendocrine Tumors (drug therapy, pathology)
• Octreotide (therapeutic use)
• Pancreatic Neoplasms (drug therapy, pathology)
• Retrospective Studies
• Somatostatin (analogs & derivatives, therapeutic use)
• Survival Analysis
• Treatment Outcome